Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer - Takeaways - MDSpire

Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer

  • By

  • Lin Lin

  • Bing Han

  • July 8, 2026

  • 0 min

Share

  • 1

    The study evaluated Ki-67, ER, and PR levels as predictors of neoadjuvant chemotherapy response in 720 breast cancer patients.

  • 2

    Patients were divided into responder and non-responder groups based on their chemotherapy efficacy assessment results.

  • 3

    High Ki-67 expression was identified as an independent predictor of favorable response to neoadjuvant chemotherapy.

  • 4

    The combined detection of Ki-67, ER, and PR showed superior predictive efficacy compared to individual markers.

  • 5

    The combined Ki-67+ER+PR model achieved an AUC of 0.853, indicating better discrimination in predicting NAC effectiveness.

Original Source(s)

Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer

  • by Lin Lin, Bing Han

  • July 8, 2026

Related Content

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

Artificial intelligence for triple-negative breast cancer from imaging to multi-omics

Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine